Application and Clinical Effectiveness of Pelvic Reconstruction in Robot-assisted Radical Cystectomy-orthotopic Ileal Neobladder in the Male

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04958343

Enrollment

100

Registered

2021-07-12

Start date

2021-07-02

Completion date

2023-07-01

Last updated

2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer

Brief summary

To study the effect of pelvic reconstruction on early return of continence after robot-assisted radical cystectomy-orthotopic ileal neobladder in the male.

Detailed description

This study will enroll male patients with bladder cancer who will undergo robot-assisted radical cystectomy-orthotopic ileal neobladder. The patients will be distributed into two comparable groups according to whether received pelvic reconstruction or not. Patient demographics and pathologic, perioperative, functional, and oncologic outcomes will be compared between the two groups.

Interventions

PROCEDUREpelvic reconstruction

After radical cystectomy, the pelvic reconstruction including the ligation of dorsal vascular complex and posterior reconstruction will be performed on patients.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Male patients aged 18 or older. 2. Patients those who are diagnosed with urothelial carcinoma. 3. Patients those who are capable of receiving radical cystectomy with orthotopic ileal neobladder. 4. Patients those who are able to cooperate and complete the follow-up. 5. Patients those who volunteer to participate in this study and sign the informed consens.

Exclusion criteria

1. Patients thsoe who are diagnosed distant metastasis before surgery. 2. Patients those who are diagnosed with other malignancies. 3. Patients those who had received pelvic radiotherapy or major pelvic operation.

Design outcomes

Primary

Measure	Time frame	Description
day-time and night-time continence rate	6 months	Patients were considered continent when they required 0 or 1 safety pad during the day or at night.

Secondary

Measure	Time frame
perioperative complication rate	3 months
operative time	24 hours
estimated blood loss	24 hours
overall survival	1 year
recurrence-free survival	1 year

Countries

China

Contacts

Primary ContactKaiwen Li, MD

likw6@mail.sysu.edu.cn+86-15989252628

Backup ContactJian Huang, MD

huangj8@mail.sysu.edu.cn+86-20-81332146

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026